The attached publication in the “Journal of Diabetic Complications & Medicine” by the authors Jonathan Rosenblum and Menachem Oberbaum describes the first ever experience with Curasite® in man. This pilot study led to the larger double blind effort that resulted in FDA approval of the product.
The pilot study showed strong evidence of a wound healing effect by Curasite to treat resistant diabetic foot ulcers (DFUs) with many patients achieving complete wound closure, results that were replicated in the larger blinded multi-center study.
The FDA has approved Curasite for the following prescription uses:
- Diabetic foot ulcers
- Leg ulcers, including venous stasis ulcers, arterial ulcers and ulcers of mixed etiology
- Full and partial thickness pressure ulcers
- 1st and 2nd degree partial thickness burns.
Curasite is also approved for the following over the counter (OTC) uses:
- Minor abrasions
- Minor lacerations
- Minor cuts
- Minor scalds and burns.
The FDA claims are extensive and importantly position Curasite as first line therapy for these patients. Due to the unprecedented efficacy of Curasite, Izun intends to pursue other indications for this remarkable wound healing product.